The melanocortin system is a useful teaching case in receptor pharmacology, because a family of closely related receptors controls strikingly unrelated physiology, and the compounds acting on them differ mainly in how cleanly they discriminate between subtypes.
All products supplied by North Specs Labs are Research Use Only and are not for human or veterinary use.
The receptor family
Five G-protein coupled receptors, MC1R through MC5R, respond to peptides derived from proopiomelanocortin.
MC1R is expressed on melanocytes and controls pigmentation. Variants in this receptor underlie red hair and fair skin phenotypes.
MC2R is the ACTH receptor in the adrenal cortex, driving cortisol production. It is the outlier in the family, responding to ACTH rather than to the melanocyte-stimulating hormones.
MC3R and MC4R are expressed in the central nervous system and regulate energy homeostasis. MC4R is the more studied; loss-of-function variants are among the more common monogenic causes of severe obesity, and MC4R agonism has been developed therapeutically for specific genetic obesity syndromes.
MC5R has roles in exocrine gland function, including sebaceous secretion.
The endogenous ligands, alpha-, beta- and gamma-melanocyte-stimulating hormone and ACTH, all derive from the same POMC precursor by differential processing, and they show only partial selectivity across subtypes. This is why synthetic analogues aiming at one subtype are pharmacologically interesting and difficult to design.
Melanotan II
Melanotan II is a cyclic heptapeptide analogue of alpha-MSH, developed originally in work on pigmentation as a route to photoprotection through induced melanogenesis without ultraviolet exposure.
It is a broad, non-selective agonist across MC1R, MC3R, MC4R and MC5R. That lack of selectivity is the defining fact about it. Pigmentation effects arise from MC1R. Effects on appetite and energy balance arise from MC3R and MC4R. Effects on sexual arousal, which were observed in early studies and were not the intended target, also arise from central melanocortin receptors.
Melanotan II has no regulatory approval in any major jurisdiction. Regulatory authorities in several countries, including the United Kingdom, Australia and others, have issued public warnings regarding products sold containing it. For laboratory purposes it remains a legitimate research chemical and a useful non-selective reference agonist; it is not a therapeutic agent.
PT-141 (bremelanotide)
PT-141 is a metabolite of melanotan II, and its history is a good illustration of how observed side effects become primary targets.
The sexual-arousal effect noted during melanotan II studies was pursued as the main endpoint. Bremelanotide, with greater relative activity at MC4R and less at MC1R, was developed on that basis and completed registered clinical development, receiving approval in the United States for a specific indication in a defined population.
The pharmacological point is that the shift in receptor selectivity, not a change in the fundamental mechanism, is what made a targeted compound out of a broad one. The two peptides are structurally close and behave very differently for that reason.
Why selectivity dominates this field
For any experiment involving melanocortin peptides, subtype selectivity determines what the result means.
An effect observed with a non-selective agonist cannot be attributed to a particular receptor without further work. Attributing an appetite effect to MC4R when the compound also engages MC3R, or a pigmentation effect to MC1R when MC5R is also active, requires either a selective compound or a selective antagonist as a control.
The practical consequence is that melanocortin work needs a compound panel rather than a single agonist. Characterising a response typically requires parallel assay across subtypes to establish the potency ratio, use of subtype-selective antagonists to establish which receptor mediates an observed effect, and comparison against the endogenous ligands as reference.
Laboratory handling
Cyclic structure. Melanotan II and bremelanotide are cyclic, with a lactam bridge. Cyclisation confers stability and constrains conformation, which is what gives these compounds their receptor profile. It also means the cyclic structure is the active species, and any ring opening during handling or storage produces a linear peptide with different pharmacology. This is not detectable by eye.
Tryptophan. The sequences contain tryptophan, which is susceptible to oxidation and to photodegradation. Protection from light is not a formality for these compounds.
Solubility. Generally water-soluble, though the cyclic constrained structure can make behaviour less predictable than a linear peptide of similar composition.
Standard practice applies: sealed, dry, dark, frozen storage; equilibration to room temperature before opening; gentle reconstitution; refrigerated single-use aliquots; and reliance on a batch-specific certificate rather than an assumed specification. For cyclic peptides in particular, mass spectrometry confirming the cyclised mass, which differs from the linear form by the mass of water, is worth checking on the certificate.
North Specs Labs supplies research-grade peptides to qualified researchers, laboratories and research institutions. All products are Research Use Only and are not for human consumption or veterinary use.
North Specs separates research education from product claims. Readers should review primary literature and institutional requirements before designing laboratory work.